Quantitative assessment of telomerase activity and human telomerase reverse transcriptase messenger RNA levels in pancreatic juice samples for the diagnosis of pancreatic cancer

Kenoki Ouchida, Kazuhiro Mizumoto, Yasuhiro Ogura, Nami Ishikawa, Eishi Nagai, Koji Yamaguchi, Masao Tanaka

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Measurement of telomerase activity is a promising diagnostic tool for pancreatic cancer. Detection of mRNA for human telomerase reverse transcriptase (hTERT), a catalytic subunit of telomerase, is also a diagnostic candidate. In the present study, we developed a telomeric repeat amplification protocol assay with real-time PCR and a protocol for quantification of hTERT mRNA with real-time PCR. To evaluate the feasibility of these methods for diagnosis of pancreatic cancer, we measured telomerase activity and hTERT expression in pancreatic cancer cell lines, pancreatic tissues, and pancreatic juice samples from patients with different pancreatic diseases. There were significant correlations between telomerase activity and hTERT expression in cell lines, tissues, and juice samples. The levels of telomerase activity and hTERT expression were significantly higher in tumoral tissues than in nontumoral tissues. In pancreatic juice specimens, some carcinoma samples showed remarkably high expression of hTERT. However, there were no significant differences in hTERT expression between patients with carcinoma and those with benign diseases, although significant differences in telomerase activity were observed. Our present results suggest that the combined assessment of hTERT and telomerase activities in pancreatic juice provides a potent diagnostic method for pancreatic cancer.

Original languageEnglish
Pages (from-to)2285-2292
Number of pages8
JournalClinical Cancer Research
Volume11
Issue number6
DOIs
Publication statusPublished - Mar 15 2005

Fingerprint

Pancreatic Juice
Telomerase
Pancreatic Neoplasms
Messenger RNA
Real-Time Polymerase Chain Reaction
Carcinoma
Cell Line
Pancreatic Diseases
human TERT protein

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Quantitative assessment of telomerase activity and human telomerase reverse transcriptase messenger RNA levels in pancreatic juice samples for the diagnosis of pancreatic cancer. / Ouchida, Kenoki; Mizumoto, Kazuhiro; Ogura, Yasuhiro; Ishikawa, Nami; Nagai, Eishi; Yamaguchi, Koji; Tanaka, Masao.

In: Clinical Cancer Research, Vol. 11, No. 6, 15.03.2005, p. 2285-2292.

Research output: Contribution to journalArticle

@article{d19562dde78048f599afd95f82681b7e,
title = "Quantitative assessment of telomerase activity and human telomerase reverse transcriptase messenger RNA levels in pancreatic juice samples for the diagnosis of pancreatic cancer",
abstract = "Measurement of telomerase activity is a promising diagnostic tool for pancreatic cancer. Detection of mRNA for human telomerase reverse transcriptase (hTERT), a catalytic subunit of telomerase, is also a diagnostic candidate. In the present study, we developed a telomeric repeat amplification protocol assay with real-time PCR and a protocol for quantification of hTERT mRNA with real-time PCR. To evaluate the feasibility of these methods for diagnosis of pancreatic cancer, we measured telomerase activity and hTERT expression in pancreatic cancer cell lines, pancreatic tissues, and pancreatic juice samples from patients with different pancreatic diseases. There were significant correlations between telomerase activity and hTERT expression in cell lines, tissues, and juice samples. The levels of telomerase activity and hTERT expression were significantly higher in tumoral tissues than in nontumoral tissues. In pancreatic juice specimens, some carcinoma samples showed remarkably high expression of hTERT. However, there were no significant differences in hTERT expression between patients with carcinoma and those with benign diseases, although significant differences in telomerase activity were observed. Our present results suggest that the combined assessment of hTERT and telomerase activities in pancreatic juice provides a potent diagnostic method for pancreatic cancer.",
author = "Kenoki Ouchida and Kazuhiro Mizumoto and Yasuhiro Ogura and Nami Ishikawa and Eishi Nagai and Koji Yamaguchi and Masao Tanaka",
year = "2005",
month = "3",
day = "15",
doi = "10.1158/1078-0432.CCR-04-1581",
language = "English",
volume = "11",
pages = "2285--2292",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

TY - JOUR

T1 - Quantitative assessment of telomerase activity and human telomerase reverse transcriptase messenger RNA levels in pancreatic juice samples for the diagnosis of pancreatic cancer

AU - Ouchida, Kenoki

AU - Mizumoto, Kazuhiro

AU - Ogura, Yasuhiro

AU - Ishikawa, Nami

AU - Nagai, Eishi

AU - Yamaguchi, Koji

AU - Tanaka, Masao

PY - 2005/3/15

Y1 - 2005/3/15

N2 - Measurement of telomerase activity is a promising diagnostic tool for pancreatic cancer. Detection of mRNA for human telomerase reverse transcriptase (hTERT), a catalytic subunit of telomerase, is also a diagnostic candidate. In the present study, we developed a telomeric repeat amplification protocol assay with real-time PCR and a protocol for quantification of hTERT mRNA with real-time PCR. To evaluate the feasibility of these methods for diagnosis of pancreatic cancer, we measured telomerase activity and hTERT expression in pancreatic cancer cell lines, pancreatic tissues, and pancreatic juice samples from patients with different pancreatic diseases. There were significant correlations between telomerase activity and hTERT expression in cell lines, tissues, and juice samples. The levels of telomerase activity and hTERT expression were significantly higher in tumoral tissues than in nontumoral tissues. In pancreatic juice specimens, some carcinoma samples showed remarkably high expression of hTERT. However, there were no significant differences in hTERT expression between patients with carcinoma and those with benign diseases, although significant differences in telomerase activity were observed. Our present results suggest that the combined assessment of hTERT and telomerase activities in pancreatic juice provides a potent diagnostic method for pancreatic cancer.

AB - Measurement of telomerase activity is a promising diagnostic tool for pancreatic cancer. Detection of mRNA for human telomerase reverse transcriptase (hTERT), a catalytic subunit of telomerase, is also a diagnostic candidate. In the present study, we developed a telomeric repeat amplification protocol assay with real-time PCR and a protocol for quantification of hTERT mRNA with real-time PCR. To evaluate the feasibility of these methods for diagnosis of pancreatic cancer, we measured telomerase activity and hTERT expression in pancreatic cancer cell lines, pancreatic tissues, and pancreatic juice samples from patients with different pancreatic diseases. There were significant correlations between telomerase activity and hTERT expression in cell lines, tissues, and juice samples. The levels of telomerase activity and hTERT expression were significantly higher in tumoral tissues than in nontumoral tissues. In pancreatic juice specimens, some carcinoma samples showed remarkably high expression of hTERT. However, there were no significant differences in hTERT expression between patients with carcinoma and those with benign diseases, although significant differences in telomerase activity were observed. Our present results suggest that the combined assessment of hTERT and telomerase activities in pancreatic juice provides a potent diagnostic method for pancreatic cancer.

UR - http://www.scopus.com/inward/record.url?scp=16844380271&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16844380271&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-04-1581

DO - 10.1158/1078-0432.CCR-04-1581

M3 - Article

C2 - 15788678

AN - SCOPUS:16844380271

VL - 11

SP - 2285

EP - 2292

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 6

ER -